248 related articles for article (PubMed ID: 22711609)
1. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
[TBL] [Abstract][Full Text] [Related]
2. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.
Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Grogan T; Elashoff D; Geist C; Silverman DH; Phelps ME; Chen W
Clin Cancer Res; 2014 Jul; 20(13):3550-9. PubMed ID: 24687922
[TBL] [Abstract][Full Text] [Related]
3. ¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
[TBL] [Abstract][Full Text] [Related]
4. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
[TBL] [Abstract][Full Text] [Related]
5. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E
Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188
[TBL] [Abstract][Full Text] [Related]
7. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W
J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180
[TBL] [Abstract][Full Text] [Related]
8. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
9.
Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and grading accuracy of
Xiao J; Jin Y; Nie J; Chen F; Ma X
BMC Cancer; 2019 Aug; 19(1):767. PubMed ID: 31382920
[TBL] [Abstract][Full Text] [Related]
11. Identify glioma recurrence and treatment effects with triple-tracer PET/CT.
Li C; Yi C; Chen Y; Xi S; Guo C; Yang Q; Wang J; Sai K; Zhang J; Ke C; Chen F; Lv Y; Zhang X; Chen Z
BMC Med Imaging; 2021 May; 21(1):92. PubMed ID: 34059015
[TBL] [Abstract][Full Text] [Related]
12. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
[TBL] [Abstract][Full Text] [Related]
13. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
14. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
16. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
[TBL] [Abstract][Full Text] [Related]
17. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas.
Karavaeva E; Harris RJ; Leu K; Shabihkhani M; Yong WH; Pope WB; Lai A; Nghiemphu PL; Liau LM; Chen W; Czernin J; Cloughesy TF; Ellingson BM
Mol Imaging Biol; 2015 Jun; 17(3):434-42. PubMed ID: 25465392
[TBL] [Abstract][Full Text] [Related]
19. Rate of change in maximum
Oughourlian TC; Yao J; Schlossman J; Raymond C; Ji M; Tatekawa H; Salamon N; Pope WB; Czernin J; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
J Neurooncol; 2020 Mar; 147(1):135-145. PubMed ID: 31981013
[TBL] [Abstract][Full Text] [Related]
20. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
